What is Drugs Made In America Acquisition Corp. Units (DMAAU)?

Drugs Made In America Acquisition Corp. Units (DMAAU) is a stock in the Financial Services sector, Shell Companies industry. View full analysis on Stocks360.

What is the current price of DMAAU?

The current price of DMAAU is $10.91. Prices are updated in real time on Stocks360.

What is DMAAU's price-to-earnings (PE) ratio?

DMAAU's trailing twelve-month PE ratio is 55.45, based on current price and earnings per share data available on Stocks360.

What is DMAAU's market capitalization?

DMAAU's market capitalization is $261,733,344.00, placing it in the small-cap tier.

Drugs Made In America Acquisition Corp. Units (DMAAU)

Stock analysis · NASDAQ · Financial Services · Shell Companies

$10.91

Market Cap

$261.73M

PE (TTM)

55.45

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.19

Day Range

$10.91 – $10.91

52-wk Range

$10.30 – $12.50

Avg Volume

N/A

Volume

0.00

Drugs Made In America Acquisition Corp. Units (DMAAU) is a publicly traded company in the Financial Services sector. Latest price: $10.91. Market cap $261.73M. Trailing PE 55.45. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 7 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-30 · $10.45 2026-10-29 · $10.91 (+4.40%)

Proprietary Signals

Signal snapshot temporarily unavailable.

About Drugs Made In America Acquisition Corp. Units

Drugs Made In America Acquisition Corp. operates as a special purpose acquisition company (SPAC). Its primary objective is to achieve a business combination, which may involve a merger, an asset acquisition, a share exchange, or a corporate restructuring, with one or more existing enterprises. The firm was established on May 23, 2024, and maintains its principal office in Fort Lauderdale, Florida.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	55.45×
P/S (TTM)	0.00×
P/B	1.59×
P/FCF (TTM)	-817.79×
EV / EBITDA	-100.70×
EV / Sales	0.00×
Earnings Yield	2.79%
Free Cash Flow Yield	-0.12%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$265.18M
Net Income (TTM)	$7.36M
Free Cash Flow (TTM)	-$323.13K
Net Debt	$929.72K
Working Capital	-$2.88M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	2.92%
Return on Invested Capital	-1.82%